Physician profile
Michael Clune
NPI 1255327490
$1,611.43
in general payments reported to CMS, 2019-2025
20 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $73.30 · 2021: $146 · 2022: $334 · 2023: $271 · 2024: $388 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $424.73 | 2019-2025 | Acrysof Iq Panoptix Uv Iol, Acrysof Iq Vivity, Rocklatan |
| Dompe US, INC. | $164.21 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $158.21 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Thea Pharma INC. | $136.14 | 2022-2025 | Iyuzeh |
| Abbvie INC. | $97.97 | 2022-2024 | Lumigan, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $87.97 | 2020-2023 | |
| Rxsight INC | $72.69 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $58.47 | 2022-2025 | |
| Rayner Intraocular Lenses Limited | $47.66 | 2022-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Johnson & Johnson Surgical Vision, INC. | $45.43 | 2021-2022 | |
| Allergan, INC. | $39.51 | 2021-2022 | |
| Akorn Operating Company LLC | $38.43 | 2021 | |
| New World Medical,INC. | $29.39 | 2023-2025 | Clearpath, Via360, Streamline |
| Eyevance Pharmaceuticals LLC | $26.02 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $25.22 | 2019 | |
| Harrow Eye, LLC | $23.85 | 2025 | Vevye |
| Horizon Therapeutics Plc | $15.80 | 2022 | |
| Omeros Corporation | $14.53 | 2019 | |
| Shire North American Group INC | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Clune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.